Suomi - suomi - Fimea (Suomen lääkevirasto)

glaxosmithkline consumer healthcare aps - terbinafine hydrochloride - emulsiovoide - 1 % - terbinafiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - valsartanum - tabletti, kalvopäällysteinen - 40 mg - valsartaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - valsartanum - tabletti, kalvopäällysteinen - 320 mg - valsartaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

novartis finland oy - triamcinolone acetonide - injektioneste, suspensio - 40 mg/ml - triamsinoloni

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - - rokotteet - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 ja 4. käyttö dengvaxia pitäisi olla virallisten suositusten mukaisesti.

Euroopan unioni - suomi - EMA (European Medicines Agency)

grunenthal gmbh - allopurinoli, lesinurad - kihti - antigout-valmisteet - duzallo on tarkoitettu aikuisten hoitoon hyperurikemia kihti potilailla, jotka eivät saavuttaneet tavoitetta seerumin virtsahappopitoisuus riittävä annos allopurinoli yksin.

Suomi - suomi - Fimea (Suomen lääkevirasto)

dr. falk pharma gmbh - rifamycin sodium - säädellysti vapauttava tabletti - 200 mg - rifamysiini

Euroopan unioni - suomi - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaani - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitromboottiset aineet - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Suomi - suomi - Fimea (Suomen lääkevirasto)

orifarm generics a/s - glucosamine sulphate sodium chloride - jauhe oraaliliuosta varten - 1.5 g - glukosamiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

navamedic asa - ceftriaxone sodium - injektiokuiva-aine, liuosta varten - 1 g - keftriaksoni